Target intelligence / Profile preview

Viral polyprotein

Molecular classification
Precursor protein, Viral protein, Enzyme substrate
01

Overview

A viral polyprotein is a large, singular polypeptide translated from a viral genome that serves as a precursor for multiple functional viral proteins. This strategy is extensively used by various virus families, including Coronaviridae, Flaviviridae, and Retroviridae, to maximize the coding efficiency of their compact genomes (UniProt, 2024). The polyprotein must be cleaved into smaller, active structural and non-structural proteins by specific viral or host proteases to facilitate viral replication and assembly. Because this proteolytic processing is essential for the production of infectious progeny, it represents a major vulnerability in the viral life cycle (NCBI Bookshelf, 2022). Antiviral drugs, specifically protease inhibitors, target the enzymes responsible for these cleavages, thereby preventing the maturation of viral proteins and effectively neutralizing the infection. This target is considered 'incorrect' in a strict sense because it is a broad category of precursor molecules across diverse viruses rather than a single specific protein, and the therapeutic focus is usually on the proteases that act upon it (PubMed, 2021).

Other names
Polyprotein precursorViral precursor proteinPolyproteinReplicase polyproteinGag-Pol polyproteinNon-structural polyprotein
02

Mechanism of action

Inhibition of proteolytic cleavage by targeting viral proteases (e.g., 3CLpro, NS3/4A, HIV Protease), which prevents the processing of the polyprotein into mature, functional viral proteins (StatPearls, 2023).

03

Biological functions

Viral replicationViral maturationProteolysisViral assemblyGenome expression
04

Disease associations

InfectionViral hepatitisAcquired immunodeficiency syndrome (AIDS)COVID-19Viral hemorrhagic fever
05

Safety considerations

Rapid development of drug resistance due to mutations in the protease or polyprotein cleavage sitesSignificant drug-drug interactions, particularly with agents that inhibit CYP3A4 (e.g., Ritonavir)Off-target inhibition of host cell proteasesMetabolic side effects including lipodystrophy and hyperlipidemiaHepatotoxicity
06

Interacting drugs

Nirmatrelvir

9 more in the full profile.

07

Biomarkers

Viral load (RNA/DNA copies)Protease gene mutationsCleavage site polymorphismsC-reactive protein (inflammatory marker in infection)

Beyond the preview

Go deeper on Viral polyprotein.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Viral polyprotein.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call